title: Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
abstract: OBJECTIVE
  Iron deficiency (ID) and anaemia are common in patients with chronic heart failure (CHF). The presence of anaemia is associated with increased morbidity and mortality in CHF, and ID is a major reason for the development of anaemia. Preliminary studies using intravenous (i.v.) iron supplementation alone in patients with CHF and ID have shown improvements in symptom status. FAIR-HF (Clinical Trials.gov NCT00520780) was designed to determine the effect of i.v. iron repletion therapy using ferric carboxymaltose on self-reported patient global assessment (PGA) and New York Heart Association (NYHA) in patients with CHF and ID.
  
  
  RESULTS
  This is a multi-centre, randomized, double-blind, placebo-controlled study recruiting ambulatory patients with symptomatic CHF with LVEF < or = 40% (NYHA II) or < or =45% (NYHA III), ID [ferritin <100 ng/mL or ferritin 100-300 ng/mL when transferrin saturation (TSAT) < 20%], and haemoglobin 9.5-13.5 g/dL. Patients were randomized in a 2:1 ratio to receive ferric carboxymaltose (Ferinject((R))) 200 mg iron i.v. or saline i.v. weekly until iron repletion (correction phase), then monthly until Week 24 (maintenance phase). Primary endpoints are (i) self-reported PGA at Week 24 and (ii) NYHA class at Week 24, adjusted for baseline NYHA class.
  
  
  CONCLUSIONS
  This study will provide evidence on the efficacy and safety of iron repletion with ferric carboxymaltose in CHF patients with ID with and without anaemia.
authors.affiliation: Department of Cardiology, Charité, Campus Virchow-Klinikum, Augustenburger Platz 1, Berlin D-13353, Germany.
authors.forename: Stefan D
authors.initials: SD
authors.lastname: Anker
authors.forename: Josep Comin
authors.initials: JC
authors.lastname: Colet
authors.forename: Gerasimos
authors.initials: G
authors.lastname: Filippatos
authors.forename: Ronnie
authors.initials: R
authors.lastname: Willenheimer
authors.forename: Kenneth
authors.initials: K
authors.lastname: Dickstein
authors.forename: Helmut
authors.initials: H
authors.lastname: Drexler
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Lüscher
authors.forename: Claudio
authors.initials: C
authors.lastname: Mori
authors.forename: Barbara
authors.initials: B
authors.lastname: von Eisenhart Rothe
authors.forename: Stuart
authors.initials: S
authors.lastname: Pocock
authors.forename: Philip A
authors.initials: PA
authors.lastname: Poole-Wilson
authors.forename: Piotr
authors.initials: P
authors.lastname: Ponikowski
mesh_terms: D000465:Algorithms; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D002985:Clinical Protocols; D004311:Double-Blind Method; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008320:Maltose / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005791:Patient Care / Q000379:methods*; D012016:Reference Values; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D005290:Ferric Compounds; C522335:ferric carboxymaltose; D008320:Maltose